MINNEAPOLIS (March 21, 2017) – OneOme continues to make strides to ensure its powerful pharmacogenomics testing is a lasting tool for patients and healthcare providers. Results from OneOme’s RightMed test, which analyzes an individual’s DNA to predict his or her response to medications, now can be integrated into a patient’s Electronic Medical Record (EMR). Since a patient’s DNA does not change over time, the results can serve as a lifelong resource for making effective prescription decisions.
Providing the capability of directly interfacing into a customer’s EMR allows healthcare providers to stay within their normal workflow instead of logging into another system for information. This integration ensures that providers can quickly access the RightMed pharmacogenomic information within a familiar electronic environment.
“OneOme’s goal is to be an accessible and long-lasting resource for patients and healthcare providers,” Paul Owen, CEO of OneOme, said. “Making a patient’s pharmacogenomic information available through their Electronic Medical Record ensures that their providers can access and harness the power of the RightMed pharmacogenomics test throughout a patient’s lifetime.”
In addition, integrating the RightMed pharmacogenomic results within the EMR not only provides access to the information, but also allows for the implementation of clinical decision support tools that alert the physician of potential issues they need to address. For example, if a provider tries to prescribe a drug that is not recommended for a patient based on their RightMed test results, they will be alerted at that moment.
The RightMed test can help people personalize their medications and avoid adverse drug reactions, which are the fourth-leading cause of death in the U.S.
OneOme is committed to making its test accessible to patients and providers. To that end, OneOme recently began offering an additional blood sample collection method that falls in line with the typical workflow for laboratory testing at many health systems.
The OneOme platform brings pharmacogenomics into routine clinical care. The goal is to help patients select the most effective prescription for their unique DNA in a timely and cost-effective manner. By using a physician-ordered blood or cheek swab test, the RightMed test gives physicians a better idea of how their patients will respond to more than 340 medications.
The RightMed test, which costs $249, analyzes 22 genes to give physicians a better idea of how their patients will respond to medications from 28 different clinical indications. The RightMed test is available globally, and anyone can get the test from their provider. While the RightMed test can provide insight for anyone, it’s particularly meaningful for patients who are taking some classes of medication, such as cardiovascular or psychiatric patients; those who are struggling with adverse drug reactions, medications that are not working; or those who are on multiple medications.
“One of OneOme’s key goals is not just to sell tests but to provide clinical information to healthcare providers and patients that is understandable and useful,” Owen added.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit www.oneome.com.